(2R)-2-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol | 83780-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (2R)-2-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol
• 英文别名: (2R)-2-(oxan-2-yloxy)propan-1-ol
• CAS: 83780-60-3
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: MKWQCXIXWYWZBA-GVHYBUMESA-N

物化性质

• 沸点：
  263.1±30.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R)-2-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol 在 Celite 、 sodium acetate 、 pyridinium chlorochromate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 14.5h， 生成 methyl (2Z,3R)-3-[tert-butyl(dimethyl)silyl]oxy-2-[(2R)-2-(oxan-2-yloxy)propylidene]decanoate
  参考文献：
  名称：

  Asymmetric synthesis of (−)-acaterin

  摘要：

  The asymmetric synthesis of (-)-acaterin, an inhibitor of acyl-CoA cholesterol acyl transferase has been achieved starting from the commercially available starting materials, octan-1-ol and methyl (R)-lactate. The key steps are a Sharpless asymmetric dihydroxylation and a Wittig olefination. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)01412-6
• 作为产物：
  描述：

  2-Methylpropyl 2-(oxan-2-yloxy)propanoate 以95的产率得到(2R)-2-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol
  参考文献：
  名称：

  Drugs Fut. 1998, 23, 1279-1286

  摘要：

  DOI：

文献信息

• Iron-Catalyzed Regio- and Stereoselective Substitution of γ,δ-Epoxy-α,β-unsaturated Esters and Amides with Grignard Reagents
  作者：Takeshi Hata、Rie Bannai、Mamoru Otsuki、Hirokazu Urabe

  DOI：10.1021/ol100022w

  日期：2010.3.5

  When γ,δ-epoxy-α,β-unsaturated esters or amides were treated with 2 equiv of Grignard reagents in the presence of 10−24 mol % FeCl2, regio- and stereoselective substitution of the epoxide moiety with the Grignard reagent occurred to give exclusively δ-hydroxy-γ-alkyl or aryl-α,β-unsaturated esters or amides in good yields.

  当在10−24 mol％FeCl 2存在下用2当量的Grignard试剂处理γ，δ-环氧-α，β-不饱和酯或酰胺时，发生了用Grignard试剂对环氧部分进行区域和立体选择性取代仅以高收率得到δ-羟基-γ-烷基或芳基-α，β-不饱和酯或酰胺。
• [EN] CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] PYRIMIDINES CYCLOALKYLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222363A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题涉及Formula I或I'的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁过载状态，如地中海贫血、镰状细胞病和血色病，以及肾脏损伤。
• SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
  申请人：Mjalli Adnan M.M.

  公开号：US20110237570A1

  公开（公告）日：2011-09-29

  The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit β-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.

  本发明提供了替代的咪唑并[1,2-b]吡啶嗪衍生物，其药学上可接受的盐，以及上述任何一种的互变异构体，这些化合物抑制β-淀粉样前体蛋白裂解酶（BACE），这可能对治疗涉及BACE的疾病，如阿尔茨海默病，具有益处。本发明还提供了包括任何这些化合物的药物组合物以及在治疗涉及BACE的疾病、疾患或症状中使用任何这些化合物和组合物的用途。
• [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222483A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁超载状态，如地中海贫血、镰状细胞病和血色病，以及肾损伤。
• AMINOPYRIMIDINE COMPOUND
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US20200095240A1

  公开（公告）日：2020-03-26

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有CaMKII抑制作用的化合物，预计可用作心脏疾病（特别是儿茶酚胺多形性室性心动过速、术后心房颤动、心力衰竭、致命性心律失常等）的预防或治疗药物。本发明涉及一种由以下公式（I）表示的化合物：其中每个符号如规范中所定义，或其盐。